LinkedIn Logo
February 19-21 2019

30+ Expert Speakers ♦ 3 Days  2 Streams ♦ 3 Workshops ♦ 10+ Hours of Networking

Day One
Wednesday, February 20, 2018

Day Two
Thursday, February 21, 2018

08.00
Chair’s Opening Remarks

  • Chee Yeun Chung Scientific Co-founder & Associate Director, Yumanity Therapeutics

Capturing Innovations in Neurodegenerative Disease Drug Development

08.15
The Power of Yeast Genetics & Protein Network Analyses to Elucidate Mechanisms of Action for Neuropathology Correcting Molecules

  • Chee Yeun Chung Scientific Co-founder & Associate Director, Yumanity Therapeutics

Synopsis

• Yumanity’s drug discovery platform: yeast phenotypic screening, target identification and patient-derived neuron validation
• Developing Yumanity’s first lead clinical candidate for Parkinson’s disease and related disorders

08.45
Discovering Targeting of Microglia to Fight Alzheimer’s Disease

Synopsis

• Human genetics suggest that dysfunctional microglia contribute to the development of Alzheimer’s disease (AD)
• At Alector, we are developing antibodies targeting microglial proteins that are genetically liked to development of AD
• The goal is to improve microglial function to facilitate removal of pathological proteins and support neuronal health and function

09.15
Morning Refreshments & Networking

10.30 The Use of Precision Medicine in Drug Development for Neurodegenerative Diseases

Daniel Klamer, Vice President, Business Development & Scientific Strategy, Anavex

11.00 Plasma-driven Therapeutics as Innovative Approaches to Treat Neurodegenerative Disorders

Steven Braithwaite, Chief Scientific Officer, Alkahest

11.30 Investigating the Role of Senescent Cells in Neurodegeneration – a Potential Therapeutic Target

Darren Baker, Assistant Professor, Mayo Clinic

10.30 Translational Strategies to Optimize Drug Development for Neurodegenerative Disorders

Holly Soares, Head, Translational Neuroscience, AbbVie

11.00 Using Genetic, Physiological & Neuroimaging Biomarkers to Select, Stratify or Interpret Patient Subgroups in Clinical Trials

Tricia Thornton-Wells, Director, Clinical Biomarkers, Translational Medicine and Biomarkers, Vertex Pharmaceuticals

11.30 Concepts of Interest &Contexts of use for Digital Drug Development Tools in Neurodegenerative Disease Clinical Trials

Jesse Cedarbaum, Vice President, Neurology Early Clinical Development, Biogen

12.00
Lunch & Networking

13.00 Blood–Brain Barrier Opening in Alzheimer’s Disease Using MR-guided Focused Ultrasound

Nir Lipsman, Assistant Professor, University of Toronto

1.30 Receptor Mediated Transport of Biotherapeutics Across the Blood-Brain-Barrier – Clinical Proof of Safety & Efficacy in Pediatric Patients with Severe MPS I

Mathias Schmidt, Chief Executive Officer, ArmaGen

13.00 Using Clinical Insights in Protein Misfolding Disease to Improve the Translational Value of Preclinical Research

Jonathan Levenson, Vice President, Preclinical Research and Development, Proclara BioSciences

13.30 Deciphering the Effects of Therapeutics for Chronic Neurodegenerative Conditions with Pathophysiology Construction-based Measures

Johan Luthman, Vice President, Neuroscience Clinical Development, Eisai

14.00
Afternoon Networking & Refreshments

Validating Next Generation Neurodegenerative Targets

15.00
SAR by Kinetics for Drug Discovery in Protein Misfolding Diseases

Synopsis

• Exploring a drug discovery method for targeting protein oligomers in neurodegenerative diseases
• The method is based on chemical kinetics and enables the identification of small molecules that reduce the rate of oligomer formation
• The method is called “structure – kinetic activity – relationship” (SKAR)
• Using SKAR it is possible to systematically develop potent small molecules to block the formation of oligomers

15.30
Round Table: Differentiating Between Contributors to Disease and Effective Drug Targets

Synopsis

This round table session will host interactive discussions on the hottest topics centred around validating effective neurodegenerative drug targets. Share your opinions and experiences with your peers to navigate significant neurodegenerative disease challenges to direct future interest and research

17.00
Chair’s Closing Remarks